Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes

Rita Anzalone, Melania Lo Iacono, Tiziana Gorgun, Cristiana Rastellini, Luca Cicalese, Felicia Farina, Giampiero La Rocca

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Type 1 diabetes is an autoimmune disease caused by the destruction of endocrine pancreas β cells by T lymphocytes, for which genetic and environmental risk factors have been proposed. Patients require daily infusions of recombinant insulin to overcome the reduced production by their own cells, but there is an increasing demand for a permanent and efficient supplementation which could better modulate the need for the hormone during the normal activities. For this reason, transplant-based therapeutic models have been proposed such as whole organ transplantation and Langerhans islets transplantation. These techniques are limited by many factors such as the lack of donors, the risks linked to the surgical practice, and the rejection reactions of the transplanted organ. Further opportunities may come from the research on stem cells. Multiple studies showed that multiple populations of stem cells may be differentiated toward pancreatic endocrine-like ones, which may express insulin in vitro and in vivo and often respond to glucose challenge. Another developing field in stem cells research is that on the immunomodulatory ability of some stem populations, in particular those defined as perinatal, derived from fetus-associated tissues usually discarded at birth. Wharton's jelly mesenchymal stem cells (WJ-MSCs), which derive from the mature mucous tissue constituting the bulk of the umbilical cord, can also differentiate toward beta cells. Moreover, these cells feature important immunomodulatory activities, which seem to be maintained also in differentiated populations, which should render these cells even more promising for cell therapy applications in type 1 diabetes. This chapter analyzes the literature regarding the features and potential of WJ-MSCs for the therapy of type 1 diabetes, in the light of multiple possible therapeutic approaches, in which cells should be used both undifferentiated and differentiated, and in cotransplantation with islets. We propose that WJ-MSCs transplantation may be useful both to regenerate β cells and also prevent the autoimmune destruction of remnant and neogenetic β cells in patients.

Original languageEnglish (US)
Title of host publicationPerinatal Stem Cells
PublisherSpringer New York
Pages313-323
Number of pages11
Volume9781493911189
ISBN (Print)9781493911189, 1493911171, 9781493911172
DOIs
StatePublished - Apr 1 2014

Fingerprint

Wharton Jelly
Medical problems
Stem cells
Mesenchymal Stromal Cells
Type 1 Diabetes Mellitus
Transplantation (surgical)
Stem Cell Research
Cell- and Tissue-Based Therapy
Therapeutics
Insulin
Tissue
Transplants
Mesenchymal Stem Cell Transplantation
Population
T-cells
Islets of Langerhans Transplantation
Endocrine Cells
Umbilical Cord
Organ Transplantation
Islets of Langerhans

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Anzalone, R., Lo Iacono, M., Gorgun, T., Rastellini, C., Cicalese, L., Farina, F., & La Rocca, G. (2014). Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes. In Perinatal Stem Cells (Vol. 9781493911189, pp. 313-323). Springer New York. https://doi.org/10.1007/978-1-4939-1118-9_28

Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes. / Anzalone, Rita; Lo Iacono, Melania; Gorgun, Tiziana; Rastellini, Cristiana; Cicalese, Luca; Farina, Felicia; La Rocca, Giampiero.

Perinatal Stem Cells. Vol. 9781493911189 Springer New York, 2014. p. 313-323.

Research output: Chapter in Book/Report/Conference proceedingChapter

Anzalone, R, Lo Iacono, M, Gorgun, T, Rastellini, C, Cicalese, L, Farina, F & La Rocca, G 2014, Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes. in Perinatal Stem Cells. vol. 9781493911189, Springer New York, pp. 313-323. https://doi.org/10.1007/978-1-4939-1118-9_28
Anzalone R, Lo Iacono M, Gorgun T, Rastellini C, Cicalese L, Farina F et al. Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes. In Perinatal Stem Cells. Vol. 9781493911189. Springer New York. 2014. p. 313-323 https://doi.org/10.1007/978-1-4939-1118-9_28
Anzalone, Rita ; Lo Iacono, Melania ; Gorgun, Tiziana ; Rastellini, Cristiana ; Cicalese, Luca ; Farina, Felicia ; La Rocca, Giampiero. / Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes. Perinatal Stem Cells. Vol. 9781493911189 Springer New York, 2014. pp. 313-323
@inbook{dc4f4f54b37d42c0a218de304f3b77c9,
title = "Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes",
abstract = "Type 1 diabetes is an autoimmune disease caused by the destruction of endocrine pancreas β cells by T lymphocytes, for which genetic and environmental risk factors have been proposed. Patients require daily infusions of recombinant insulin to overcome the reduced production by their own cells, but there is an increasing demand for a permanent and efficient supplementation which could better modulate the need for the hormone during the normal activities. For this reason, transplant-based therapeutic models have been proposed such as whole organ transplantation and Langerhans islets transplantation. These techniques are limited by many factors such as the lack of donors, the risks linked to the surgical practice, and the rejection reactions of the transplanted organ. Further opportunities may come from the research on stem cells. Multiple studies showed that multiple populations of stem cells may be differentiated toward pancreatic endocrine-like ones, which may express insulin in vitro and in vivo and often respond to glucose challenge. Another developing field in stem cells research is that on the immunomodulatory ability of some stem populations, in particular those defined as perinatal, derived from fetus-associated tissues usually discarded at birth. Wharton's jelly mesenchymal stem cells (WJ-MSCs), which derive from the mature mucous tissue constituting the bulk of the umbilical cord, can also differentiate toward beta cells. Moreover, these cells feature important immunomodulatory activities, which seem to be maintained also in differentiated populations, which should render these cells even more promising for cell therapy applications in type 1 diabetes. This chapter analyzes the literature regarding the features and potential of WJ-MSCs for the therapy of type 1 diabetes, in the light of multiple possible therapeutic approaches, in which cells should be used both undifferentiated and differentiated, and in cotransplantation with islets. We propose that WJ-MSCs transplantation may be useful both to regenerate β cells and also prevent the autoimmune destruction of remnant and neogenetic β cells in patients.",
author = "Rita Anzalone and {Lo Iacono}, Melania and Tiziana Gorgun and Cristiana Rastellini and Luca Cicalese and Felicia Farina and {La Rocca}, Giampiero",
year = "2014",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-1118-9_28",
language = "English (US)",
isbn = "9781493911189",
volume = "9781493911189",
pages = "313--323",
booktitle = "Perinatal Stem Cells",
publisher = "Springer New York",

}

TY - CHAP

T1 - Wharton's Jelly Mesenchymal stem cells for the treatment of type 1 diabetes

AU - Anzalone, Rita

AU - Lo Iacono, Melania

AU - Gorgun, Tiziana

AU - Rastellini, Cristiana

AU - Cicalese, Luca

AU - Farina, Felicia

AU - La Rocca, Giampiero

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Type 1 diabetes is an autoimmune disease caused by the destruction of endocrine pancreas β cells by T lymphocytes, for which genetic and environmental risk factors have been proposed. Patients require daily infusions of recombinant insulin to overcome the reduced production by their own cells, but there is an increasing demand for a permanent and efficient supplementation which could better modulate the need for the hormone during the normal activities. For this reason, transplant-based therapeutic models have been proposed such as whole organ transplantation and Langerhans islets transplantation. These techniques are limited by many factors such as the lack of donors, the risks linked to the surgical practice, and the rejection reactions of the transplanted organ. Further opportunities may come from the research on stem cells. Multiple studies showed that multiple populations of stem cells may be differentiated toward pancreatic endocrine-like ones, which may express insulin in vitro and in vivo and often respond to glucose challenge. Another developing field in stem cells research is that on the immunomodulatory ability of some stem populations, in particular those defined as perinatal, derived from fetus-associated tissues usually discarded at birth. Wharton's jelly mesenchymal stem cells (WJ-MSCs), which derive from the mature mucous tissue constituting the bulk of the umbilical cord, can also differentiate toward beta cells. Moreover, these cells feature important immunomodulatory activities, which seem to be maintained also in differentiated populations, which should render these cells even more promising for cell therapy applications in type 1 diabetes. This chapter analyzes the literature regarding the features and potential of WJ-MSCs for the therapy of type 1 diabetes, in the light of multiple possible therapeutic approaches, in which cells should be used both undifferentiated and differentiated, and in cotransplantation with islets. We propose that WJ-MSCs transplantation may be useful both to regenerate β cells and also prevent the autoimmune destruction of remnant and neogenetic β cells in patients.

AB - Type 1 diabetes is an autoimmune disease caused by the destruction of endocrine pancreas β cells by T lymphocytes, for which genetic and environmental risk factors have been proposed. Patients require daily infusions of recombinant insulin to overcome the reduced production by their own cells, but there is an increasing demand for a permanent and efficient supplementation which could better modulate the need for the hormone during the normal activities. For this reason, transplant-based therapeutic models have been proposed such as whole organ transplantation and Langerhans islets transplantation. These techniques are limited by many factors such as the lack of donors, the risks linked to the surgical practice, and the rejection reactions of the transplanted organ. Further opportunities may come from the research on stem cells. Multiple studies showed that multiple populations of stem cells may be differentiated toward pancreatic endocrine-like ones, which may express insulin in vitro and in vivo and often respond to glucose challenge. Another developing field in stem cells research is that on the immunomodulatory ability of some stem populations, in particular those defined as perinatal, derived from fetus-associated tissues usually discarded at birth. Wharton's jelly mesenchymal stem cells (WJ-MSCs), which derive from the mature mucous tissue constituting the bulk of the umbilical cord, can also differentiate toward beta cells. Moreover, these cells feature important immunomodulatory activities, which seem to be maintained also in differentiated populations, which should render these cells even more promising for cell therapy applications in type 1 diabetes. This chapter analyzes the literature regarding the features and potential of WJ-MSCs for the therapy of type 1 diabetes, in the light of multiple possible therapeutic approaches, in which cells should be used both undifferentiated and differentiated, and in cotransplantation with islets. We propose that WJ-MSCs transplantation may be useful both to regenerate β cells and also prevent the autoimmune destruction of remnant and neogenetic β cells in patients.

UR - http://www.scopus.com/inward/record.url?scp=84929832392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929832392&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1118-9_28

DO - 10.1007/978-1-4939-1118-9_28

M3 - Chapter

AN - SCOPUS:84929832392

SN - 9781493911189

SN - 1493911171

SN - 9781493911172

VL - 9781493911189

SP - 313

EP - 323

BT - Perinatal Stem Cells

PB - Springer New York

ER -